Courses

A five day course covering the biology, science and mechanisms behind the diverse range of targeted drug treatments and new immunotherapies for cancer with an overview of how they work – focusing on the science behind them – and giving descriptions of which treatments are relevant to each of the most common solid tumours and haematological cancers.

The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. This two session course provides an understanding of the concepts that underlie precision cancer medicine and both its promise and limitations.

Please note that this course has been rearranged to start in February 2025

Please note that this course has been moved to Wednesday 27th November 2024

This course will introduce the science behind many forms of immunotherapy, including immune checkpoint inhibitors, treatment vaccines, and CAR T cells.

The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. This two session course provides an understanding of the concepts that underlie precision cancer medicine and both its promise and limitations.

This 3-hour virtual course emphasises the progress made in developing novel immunotherapies for solid tumours, such as CAR T cell therapy, TCR-engineered T cell therapy, tumour infiltrating lymphocytes, T cell engagers, and vaccine-based treatments.

This course gives cancer nurses and trial staff the knowledge and confidence to discuss a wide range of targeted cancer treatments and immunotherapies with patients and colleagues.

Knowledge gained through this course will enhance learners’ understanding of cancer biology, the mechanism of action of systemic cancer treatments, and the use of biomarkers to select the best treatments for each patient and as a result empower staff to feel confident when communicating with patients and their families, and with clinical and non-clinical colleagues.

This course describes how bowel cancer comes about, and explains the reasons why some patients might be given treatments such as EGFR-targeted antibodies (cetuximab and panitumumab), angiogenesis inhibitors (bevacizumab and regorafenib), or immune checkpoint inhibitors (pembrolizumab) as part of their treatment.

This course provides an overview of the targeted therapies and immunotherapies given to some people with oesophageal, stomach, pancreatic or liver cancer, or cancers of the biliary system